News

The global clinical trial technology company has centralized development of its SaaS solutions in its Boston office due to the area’s unique combination of expert development talent, biopharmaceutical

Her addition to the senior leadership team further solidifies EAS as the leading consulting company in regulatory matters pertaining to all FDA regulated areas including OTCs, pharmaceuticals, cosmetics,

HPPI will study the efficacy and safety of twice-daily dosing of SUBA-Itraconazole Oral Capsules as a potential therapy for basal cell carcinoma (BCC) in patients with basal cell

Of 203 total subjects enrolled in VTI-208, 96 were randomized to the treated group and 107 were randomized to the control group. A hazard ratio of 1.027 (slightly

Both studies met all primary immunogenicity endpoints, demonstrating robust immune responses against certain invasive meningococcal B strains after the vaccine dose series. Safety and tolerability data from both

The Dickkopf-3 gene produces a protein called Reduced Expression in Immortalized Cells protein (REIC), which is vital in the downstream mechanism of apoptosis and when absent cancer cells

The PDC platform has showed highly selective cancer targeting both preclinically in more than 60 in vivo cancer models, and subsequently confirmed clinically in over ten cancer types.

Currently, SER-109 is being examined as a new therapeutic modality to treat recurrent CDI by correcting a dysbiosis of the human microbiome, which is an underlying cause of

In July, ixazomib was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The MAA was based on the results of the first